Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) have been given a consensus rating of “Buy” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $27.17.
IMNM has been the subject of several recent research reports. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Monday, March 10th. Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target on the stock.
Read Our Latest Stock Analysis on Immunome
Insider Buying and Selling
Hedge Funds Weigh In On Immunome
Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. grew its stake in Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock valued at $359,000 after acquiring an additional 1,520 shares during the period. Sequoia Financial Advisors LLC raised its holdings in shares of Immunome by 11.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after acquiring an additional 2,000 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Immunome by 5.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after acquiring an additional 2,005 shares during the period. Intech Investment Management LLC raised its holdings in shares of Immunome by 26.5% during the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after acquiring an additional 3,974 shares during the period. Finally, Wellington Management Group LLP raised its holdings in shares of Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after acquiring an additional 4,874 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.
Immunome Stock Up 3.1 %
Shares of IMNM stock opened at $9.04 on Tuesday. The company has a 50 day moving average price of $9.93 and a 200-day moving average price of $11.71. Immunome has a 52 week low of $8.39 and a 52 week high of $26.70. The firm has a market capitalization of $721.18 million, a PE ratio of -1.11 and a beta of 1.93.
Immunome Company Profile
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
See Also
- Five stocks we like better than Immunome
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Can TikTok Stock Picks Really Make You Rich?
- 3 Tickers Leading a Meme Stock Revival
- The “Quality” Rotation: Back to Basics Investing
- What is the Euro STOXX 50 Index?
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.